SAHA, an HDAC Inhibitor, Synergizes with Tacrolimus to Prevent Murine Cardiac Allograft Rejection

Overview

Journal Cell Mol Immunol

Date 2012 Aug 28

PMID 22922441

Citations 14

Authors

Xin Zhang

Shu Han

Yindong Kang

Meng Guo

Shanjuan Hong

Fang Liu

Shangxi Fu

Liming Wang

Quan-Xing Wang

Affiliations

Soon will be listed here.

Abstract

Suberoylanilide hydroxamic acid (SAHA), as a histone deacetylase (HDAC) inhibitor (HDACi), was recently found to exhibit an immunosuppressive effect. However, whether SAHA can synergize with calcineurin inhibitors (CNIs) to inhibit allograft rejection and its underlying mechanism remain elusive. In this study, we demonstrated the synergistic effects of SAHA and non-therapeutic dose of tacrolimus (FK506) in prolonging the allograft survival in a murine cardiac transplant model. Concomitant intragraft examination revealed that allografts from SAHA-treated recipients showed significantly lower levels of IL-17 expression, and no discernable difference for IL-17 expressions was detected between SAHA- and SAHA/FK506-treated allograft as compared with allografts from FK506-treated animals. In contrast, administration of FK506 significantly suppressed interferon (IFN)-γ but increased IL-10 expression as compared with that of SAHA-treated animals, and this effect was independent of SAHA. Interestingly, SAHA synergizes with FK506 to promote Foxp3 and CTLA4 expression. In vitro, SAHA reduced the proportion of Th17 cells in isolated CD4⁺ T-cell population and decreased expressions of IL-17A, IL-17F, STAT3 and RORγt in these cells. Moreover, SAHA enhances suppressive function of regulatory T (Treg) cells by upregulating the expression of CTLA-4 without affecting T effector cell proliferation, and increased the proportion of Treg by selectively promoting apoptosis of T effector cells. Therefore, SAHA, a HDACi, may be a promising immunosuppressive agent with potential benefit in conjunction with CNI drugs.

Citing Articles

Immunometabolism of Liver Xenotransplantation and Prospective Solutions.

Deng S, Zhang Y, Shen S, Li C, Qin C Adv Sci (Weinh). 2025; 12(9):e2407610.

PMID: 39912334 PMC: 11884532. DOI: 10.1002/advs.202407610.

Epigenetic regulation of tumor immunity.

Pang L, Zhou F, Liu Y, Ali H, Khan F, Heimberger A J Clin Invest. 2024; 134(12).

PMID: 39133578 PMC: 11178542. DOI: 10.1172/JCI178540.

STXBP3 and GOT2 predict immunological activity in acute allograft rejection.

Yao Q, Wang C, Wang Y, Xiang W, Chen Y, Zhou Q Front Immunol. 2022; 13:1025681.

PMID: 36532048 PMC: 9751189. DOI: 10.3389/fimmu.2022.1025681.

Single-cell transcriptomic identified HIF1A as a target for attenuating acute rejection after heart transplantation.

Chang Y, Li X, Cheng Q, Hu Y, Chen X, Hua X Basic Res Cardiol. 2021; 116(1):64.

PMID: 34870762 DOI: 10.1007/s00395-021-00904-5.

Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH.

Kumar S, Sarthi P, Mani I, Ashraf M, Kang M, Kumar V Cells. 2021; 10(9).

PMID: 34571899 PMC: 8466810. DOI: 10.3390/cells10092250.

References

Tao R, de Zoeten E, Ozkaynak E, Chen C, Wang L, Porrett P . Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med. 2007; 13(11):1299-307. DOI: 10.1038/nm1652. View

Xiao L, Fu Z, Liu F, Zhang L, Shi X, Shen X . Suppression of allograft rejection by Tim-1-Fc through cross-linking with a novel Tim-1 binding partner on T cells. PLoS One. 2011; 6(7):e21697. PMC: 3130052. DOI: 10.1371/journal.pone.0021697. View

Moon C, Kim S, Park K, Choi B, Lee H, Park J . Use of epigenetic modification to induce FOXP3 expression in naïve T cells. Transplant Proc. 2009; 41(5):1848-54. DOI: 10.1016/j.transproceed.2009.02.101. View

Ropero S, Esteller M . The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2009; 1(1):19-25. PMC: 5543853. DOI: 10.1016/j.molonc.2007.01.001. View

Marks P, Richon V, Miller T, Kelly W . Histone deacetylase inhibitors. Adv Cancer Res. 2004; 91:137-68. DOI: 10.1016/S0065-230X(04)91004-4. View

de Zoeten E, Wang L, Butler K, Beier U, Akimova T, Sai H . Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol. 2011; 31(10):2066-78. PMC: 3133361. DOI: 10.1128/MCB.05155-11. View

Clipstone N, Crabtree G . Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature. 1992; 357(6380):695-7. DOI: 10.1038/357695a0. View

Korn T, Bettelli E, Oukka M, Kuchroo V . IL-17 and Th17 Cells. Annu Rev Immunol. 2009; 27:485-517. DOI: 10.1146/annurev.immunol.021908.132710. View

Abadja F, Sarraj B, Ansari M . Significance of T helper 17 immunity in transplantation. Curr Opin Organ Transplant. 2011; 17(1):8-14. PMC: 3539809. DOI: 10.1097/MOT.0b013e32834ef4e4. View

10.

Casey M, Meier-Kriesche H . Calcineurin inhibitors in kidney transplantation: friend or foe?. Curr Opin Nephrol Hypertens. 2011; 20(6):610-5. DOI: 10.1097/MNH.0b013e32834b4343. View

11.

Wang Q, Liu Y, Li X . Simplified technique for heterotopic vascularized cervical heart transplantation in mice. Microsurgery. 2004; 25(1):76-9. DOI: 10.1002/micr.20082. View

12.

Minucci S, Pelicci P . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6(1):38-51. DOI: 10.1038/nrc1779. View

13.

Li Y, Shi Y, Huang Z, Bai Y, Niu Q, Cai B . CNI induced Th17/Treg imbalance and susceptibility to renal dysfunction in renal transplantation. Int Immunopharmacol. 2011; 11(12):2033-8. DOI: 10.1016/j.intimp.2011.08.015. View

14.

Singh B, Zhang G, Hwa Y, Li J, Dowdy S, Jiang S . Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther. 2010; 10(6):935-54. PMC: 3273412. DOI: 10.1586/era.10.62. View

15.

Bosisio D, Vulcano M, Del Prete A, Sironi M, Salvi V, Salogni L . Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J Leukoc Biol. 2008; 84(6):1540-8. PMC: 2614600. DOI: 10.1189/jlb.0708401. View

16.

Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi A . Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002; 346(8):580-90. DOI: 10.1056/NEJMra011295. View

17.

de Zoeten E, Wang L, Sai H, Dillmann W, Hancock W . Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology. 2009; 138(2):583-94. PMC: 3369426. DOI: 10.1053/j.gastro.2009.10.037. View

18.

Codd R, Braich N, Liu J, Soe C, Pakchung A . Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A. Int J Biochem Cell Biol. 2008; 41(4):736-9. DOI: 10.1016/j.biocel.2008.05.026. View

19.

McKinsey T . The biology and therapeutic implications of HDACs in the heart. Handb Exp Pharmacol. 2011; 206:57-78. DOI: 10.1007/978-3-642-21631-2_4. View

20.

Schildberg F, Hagmann C, Bohnert V, Tolba R . Improved transplantation outcome by epigenetic changes. Transpl Immunol. 2010; 23(3):104-10. DOI: 10.1016/j.trim.2010.05.001. View